Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant

Ann-Kathrin Reuschl; Lucy Thorne; Lorena Zuliani Alvarez; Mehdi Bouhaddou; Kirsten Obernier; Joseph Hiatt; Margaret Soucheray; Jane Turner; Jacqueline Fabius; Gina T. Nguyen; Danielle Swaney; Romel Rosales; Kris M. White; Pablo Aviles; Ilsa T Kirby; James E Melnyk; Ying Shi; Ziyang Zhang; Kevan Shokat; Adolfo Garcia-Sastre; Clare Jolly; Gregory J Towers; Nevan J Krogan.
Preprint en Inglés | PREPRINT-BIORXIV | ID: ppbiorxiv-427991

Documentos relacionados

  1. Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant.
  2. The Life of SARS-CoV-2 Inside Cells: Replication-Transcription Complex Assembly and Function.
  3. Current Therapeutics for COVID-19, What We Know about the Molecular Mechanism and Efficacy of Treatments for This Novel Virus.
  4. Early introductions and transmission of SARS-CoV-2 variant B.1.1.7 in the United States.
  5. Role of toll-like receptors in the pathogenesis of COVID-19: Current and future perspectives.
  6. COV2Var, a function annotation database of SARS-CoV-2 genetic variation.
  7. Outbreak of COVID-19: A Detailed Overview and Its Consequences.
  8. Features of Pathobiology and Clinical Translation of Approved Treatments for Coronavirus Disease 2019.
  9. SARS-CoV-2 variant spike and accessory gene mutations alter pathogenesis.
  10. Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19.